Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama. 2007;298:299 308. S4.5.2-4. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglyc- erides and risk of ischemic stroke in the general population. Jama. 2008;300:2142 52. S4.5.2-5. Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-anal- ysis of the impact of statin therapy on low-density lipoprotein cho- lesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444 8. S4.5.2-6. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581 90. S4.5.2-7. Christian JB, Arondekar B, Buysman EK, et al. Clinical and eco- nomic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450 61. S4.5.2-8. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers choles- terol saturation index of gallbladder bile. Hepatology. 1988;8: 1147 50. S4.5.2-9. Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutri- tion therapy is the essential cornerstone for effective treatment of refractory severe hypertriglyceridemia regardless of pharmaceuti- cal treatment: evidence from a lipid management program. J Clin Lipidol. 2015;9:559 67. S4.5.2-10. Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipo- proteinemia. A descriptive study in 32 families. Ann Intern Med. 1977;87:526 34. S4.5.2-11. Steiner G, Adelman AG, Silver MD. Early coronary atheroscle- rosis in primary type V hyperlipoproteinemia. Can Med Assoc J. 1971;105:1172 4. S4.5.2-12. Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovas- cular mortality in treated patients with severe hypertriglyceri- daemia: a long-term prospective registry study. Atherosclerosis. 2010;211:618 23. S4.5.2-13. 